Objective.
Design. Analysis of baseline data from the Fibromyalgia Activity Study with TENS (FAST), a randomized controlled trial of the efficacy of transcutaneous electrical nerve stimulation.
Setting. Dual site, university-based outpatient clinics.
Subjects. Women aged 20 to 67 years diagnosed with fibromyalgia.
Methods. Participants completed the Revised Fibromyalgia Impact Questionnaire (FIQR) and 10 PROMIS static SF instruments. Internal consistency was calculated using Cronbach alpha. Convergent validity was examined against the FIQR using Pearson correlation and multiple regression analysis.
Results. PROMIS static SF instruments had fair to high internal consistency (Cronbach a 5 0.58 to 0.94, P < 0.05). PROMIS 'physical function' domain score was highly correlated with FIQR 'function' score (r 5 20.73). The PROMIS 'total' score was highly correlated with the FIQR total score (r 5 20.72). Correlations with FIQR total score of each of the three PROMIS domain scores were r 5 20.65 for
Introduction

The
Patient-Reported Outcomes Measurement Information System (PROMIS) is a system of item banks developed by the National Institutes of Health to standardize measurement and comparison of patientreported outcomes across a spectrum of chronic conditions [1, 2] . Item banks are sets of calibrated questions that were developed using item-response theory, and operationally define and quantify health constructs related to the "illness experience" [1, 3, 4] . PROMIS instruments can be completed using either computer adaptive tests or short-form (SF) instruments.
Static SF instruments have demonstrated reliability with the overall item banks used in computer adaptive testing, and are highly correlated with existing validated measures of emotional distress, pain, fatigue, physical function, social participation, sleep abnormalities, and global health in a variety of clinical populations [3, 5, [6] [7] [8] [9] [10] . In a mixed clinical population of adults with a reported chronic pain condition, which included participants with rheumatoid arthritis and osteoarthritis, the Pain Behavior and Pain Interference large item banks and static SFs are highly correlated with validated assessments of pain interference and severity (Brief Pain Inventory [BPI] Severity, r ¼ 0.81; BPI Interference, r ¼ 0.85 to 0.90; SF-36 Bodily Pain Scale, r ¼ À0.78 to À0.86) [3, 6] . However, the reliability and validity of PROMIS static SF instruments addressing physical function, global health, and other symptoms specific to individuals with fibromyalgia have not been evaluated.
Fibromyalgia is characterized by diffuse, persistent musculoskeletal pain and tenderness [11, 12] . Fatigue, sleep impairments, and psychological factors such as anxiety and depression are also hallmark symptoms of fibromyalgia, in addition to chronic pain [11] [12] [13] . The Outcome Measures in Rheumatology (OMERACT) and the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) groups identified the most clinically relevant patient-reported outcomes (core symptom domains) in patients with fibromyalgia, and recommended valid and reliable assessments for each core symptom domain for clinical and research use [14] [15] [16] [17] . PROMIS instruments have been suggested for use in individuals with fibromyalgia because the item banks represent constructs relevant to the core symptom domains of fibromyalgia outlined by the OMERACT group [17, 18] . However, the psychometric properties of the PROMIS static SF instruments compared with legacy measures like the Revised Fibromyalgia Impact Questionnaire (FIQR) have not been assessed in this patient population.
Therefore, the primary objective of this study was to evaluate the reliability (internal consistency) and construct (convergent) validity of 10 PROMIS static SF instruments for assessing disease severity in a cohort of women with fibromyalgia. The principal method of examining convergent validity was to determine correlations between PROMIS static SF instruments and the FIQR, a widely used legacy measure of disease severity [19] .
Methods
Study Design
The current study is a prespecified analysis of baseline data from the Fibromyalgia Activity Study with TENS (FAST), a phase II dual site, randomized controlled trial of the efficacy of transcutaneous electrical nerve stimulation (TENS) in women with fibromyalgia. The study protocol has been previously described in detail [20] . Data were collected prior to treatment group randomization.
Participants
Women with fibromyalgia were recruited from University of Iowa Hospitals and Clinics, Vanderbilt University Medical Center, and neighboring communities to participate (N ¼ 106). All participants provided written informed consent as approved by Institutional Review Boards for both sites. Women were included in the study if they were between 18 and 70 years old, English speaking, diagnosed with fibromyalgia based on the American College of Rheumatology (ACR) criteria [11] , had a history of cervical or lumbar pain, and had a stable medical treatment regimen 4 weeks prior to participation as well as throughout the duration of the study. The cervical and lumbar spine regions are common sites of pain in people with fibromyalgia, and are the target treatment areas for the primary study. Additionally, axial pain is part of the 1990 ACR diagnostic criteria [11] . Participants were excluded for prior TENS use in the last 5 years, self-reported pain intensity of less than 4 out of 10 on the Numeric Rating Scale, unstable medical or psychiatric issues, spinal fusion or metal in the spine (cervical, thoracic, or lumbar), or dermal sensitivity to adhesives or nickel products.
Data Collection Procedure
Instrument Protocol
Participant demographics were collected at Visit 1 using an online survey in the Research Electronic Data Capture (REDCap) system [20] . On Visit 2, all participants were asked to complete a battery of online assessments to evaluate disease severity, general health, pain behavior, pain interference, sleep impairment, pain catastrophizing, perceived physical activity level, fatigue, and fear of movement; details of these assessments have been published [20] . The FIQR was administered on Visits 1 and 2 and 10 PROMIS static SF instruments on Visit 2 [20] . FIQR data from Visit 2 are used in the analysis.
Legacy Instrument-FIQR
The FIQR evaluates disease severity and impact on physical function in individuals with fibromyalgia. The FIQR contains 21 items divided into three domains: 1) 'function' (9 items); 2) 'overall impact' (2 items); and 3) 'symptoms' (10 items) [19, 21] . Each item is rated on a scale from 0 (best) to 10 (worst). Scores for each domain are summed. Summative scores for the 'function' domain range from 0 to 90, which are weighted for the FIQR total score by adding the scores and dividing by three. The summative score for the 'overall impact' domain ranges from 0 to 20, and serves as the total score for items within that domain. Finally, summative scores for the 'symptom' domain range from 0 to 100, and are weighted for the FIQR total score by adding the scores and dividing by two. The total score of the FIQR is the sum of the weighted domain scores. Higher scores indicate greater disease severity and impaired physical function. Reliability and convergent validity of the FIQR individual domain and total scores have been well established in fibromyalgia. Internal consistency of FIQR items measured using Cronbach alpha was 0.95, with individual item correlations ranging from 0.56 to 0.93 [19] . Convergent validity of items on the FIQR was established using the Fibromyalgia Impact Questionnaire (FIQ) and the Short Form Health Survey (SF-36) subscales [19] . The domains for the FIQ and FIQR were moderately to highly correlated (r ¼ 0.46 to 0.88), while subscale items on the FIQR had low to high correlations with SF-36 subscale items (r ¼ 0.11 to 0.80) [19] .
PROMIS Instruments
Participants completed the following PROMIS static short-forms (SFs) thought to best align with relevant constructs within the core symptom domains of fibromyalgia [17, 18] : Physical Function 10a, SF v1.0-1.1 Global, Fatigue 7a, Pain Interference 6b, Pain Behavior 7a, Sleep Disturbance 8b, Sleep Impairment 8a, and Emotional Distress (Anxiety 8a, and Depression 8b). The static SFs were used to standardize the questionnaire testing time for participants. The PROMIS static SF instruments contain six to ten questions. Responses are scored on a Likert scale with the exception of the pain rating subscale. The pain rating subscale is scored using an 11-point numeric rating scale, with anchors ranging from 0 (no pain) to 10 (worst pain imaginable). The outcome score formula was used to score the PROMIS static SF instruments. The raw sum of scores is multiplied by the number of items on the static SF, with the resulting number being divided by number of items answered. If 20% of the items were unanswered, the subject's score was not used. However, all participants' scores were used as only one subject left one question unanswered. The outcome score is then converted to a T-score with a mean of 50 and a standard deviation (SD) of 10. In the PROMIS scoring system, scores higher than 50 indicate more of the concept being studied and below 50 is less of the concept. More specifically, for positively worded constructs such as global health, better perceived health would have a higher score than 50. However, for negatively worded constructs such as anxiety, a score higher than 50 would indicate more anxiety than average [22] . More detailed information on the PROMIS static SF instruments can be accessed at www.healthmeasures.net/explore-meas urement-systems/promis.
Statistical Analyses
All statistical analyses were performed using SAS Version 9.4 statistical software (SAS Institute Inc, Cary, NC). Normal distribution of FIQR and PROMIS scores was assessed using histograms. Descriptive statistics for participant demographics, domain scores for both instruments, and total scores for the FIQR and PROMIS static SF instruments were calculated for the entire cohort. Internal consistency, the degree to which items on an instrument measure the same construct, was calculated using Cronbach alpha [8, 23] . Convergent validity of PROMIS static SFs were validated against the FIQR 'function,' 'overall impact,' and 'symptom' domains using Pearson correlation and multiple regression analysis.
Results
Descriptive Statistics
This study included 106 women with fibromyalgia that met the inclusion criteria and completed both the FIQR and PROMIS static SF instruments. The demographic characteristics of the study participants are presented in Table 1 . Descriptive statistics for the FIQR domains, including the subscale scores that comprise the 'symptom' domain, are shown in Table 2 . The mean FIQR Total score was 57.0 (SD 16.5), with mean scores of 15.6 (SD 6.0) for 'function,' 11.3 (SD 4.8) for 'overall impact,' and 30.1 (SD 8.0) for 'symptom' domains. The mean scores for the PROMIS 'physical function' and 'global' domains were 36.5 (SD 4.8) and 36.8 (SD 5.4), respectively. The PROMIS 'symptom' score mean was 39.5 (SD 5.6) with range of 23.8-53.5, and mean scores for the PROMIS individual symptom subscales ranged from 57.3 (SD 8.6) to 65.2 (SD 5.3). The mean scores of PROMIS static SF instruments that correspond to the FIQR 'physical function' and 'overall impact' domains and symptom subscales are provided in Table 3 , and histograms of the three PROMIS domain scores and FIQR Total scores are provided in Figure 1 .
Internal Consistency
PROMIS static SF instruments had fair to excellent internal consistency (Cronbach a ¼ 0.58 to 0.94, P < 0.05). The PROMIS Emotional Distress-Depression 8b static SF had the highest internal consistency (Cronbach a ¼ 0.94), and the SF v1.0-1.1 Global instrument had the lowest internal consistency (Cronbach a ¼ 0.58) ( Table 3) .
Convergent Validity
Assessment of convergent validity of PROMIS static SFs was performed using correlation analyses with the FIQR domain scores and the FIQR Total score. Individual subscales from all of the PROMIS static SF modules were first correlated with individual subscales from the FIQR to establish three independent PROMIS domains analogous to the FIQR domains. This included correlating: 1) the FIQR 'function' score with the PROMIS 'physical function' score; 2) the FIQR 'overall impact' score with the PROMIS 'global physical' and 'global mental' scores; and 3) the FIQR 'symptom' subscales with the corresponding PROMIS Fatigue, Sleep Disturbance, Sleep Impairment, Depression, Anxiety, Pain Behavior, and Pain Interference static SF scores. The Pearson correlation coefficient estimates from this analysis, with 95% confidence intervals (CI), are presented in Table 4 .
The PROMIS 'physical function' score was highly correlated with the FIQR 'function' score with Pearson correlation (r) of À0.73 (95% CI: À0.81, À0.63). The correlations of the PROMIS 'global physical' score (r ¼ À0.53; 95% CI: À0.65, À0.37), and 'global mental' score (r ¼ À0.47; 95% CI: À0.61, À0.31) with FIQR 'overall impact' score were mild to moderate. A slightly Table 4 .
Finally, a PROMIS 'total' score was computed and examined for correlation with FIQR total score. Results from these analyses are illustrated in Figures 2 and 3 . The PROMIS 'total' score was calculated as the weighted sum of PROMIS 'physical function,' 'global,' and 'symptom' scores. The 'symptom' subscale was reverse scored prior to calculation. The weighted sum of the PROMIS domain scores were derived using the following formula: 0.3(Physical Function) þ 0.2(Global Mean) þ 0.5(Symptom). These weights were the same Figure 3A , B, and C, respectively).
Multiple Regression Analysis
Multiple regression analysis was performed to determine the incremental contribution of the PROMIS 'physical,' 'global,' and 'symptom' domains to the variance of FIQR total score. The regression model for FIQR total score that included PROMIS 'physical function,' 'global,' and 'symptom' scores explained 58% of the FIQR total score variance. With 'physical function' entered first in the model (R-square ¼ 41.9%), the incremental R-square adding a second variable was 13.9% for global, and 12.6% for symptom (see Table 5 ). Due to the high collinearity of the PROMIS 'symptom' and 'global' domain scores (r ¼ 0.73), the incremental rsquare adding symptom was <2.6% with global already in the model. This was not the case for 'physical function,' which had an incremental r-square of 14.6% when entered with global and symptom already in the model.
Discussion
The primary aim of this investigation was to determine the reliability and construct (convergent) validity of select PROMIS static SF instruments for assessment of disease severity and global disease impact in a cohort of women with fibromyalgia. To our knowledge, this is the first investigation to evaluate the psychometric properties of the PROMIS static SF modules in adults with fibromyalgia. Using a novel method of analysis, key findings have emerged. First, all of the PROMIS static SF instruments used in this study have fair to excellent internal consistency of item responses in women with fibromyalgia, and scores from the PROMIS static SF instruments are indicative of greater symptom severity in this population. Secondly, many of the PROMIS static SF instruments used in this study demonstrate convergent validity with subscale items on the FIQR. Finally, the PROMIS Physical Function static SF accounted for the greatest variance in the FIQR total score out of the 10 PROMIS static SFs included in this study. Together these findings suggest that select PROMIS static SF instruments collectively measure relevant constructs related to disease severity and the "illness experience" in women with fibromyalgia [4] . Additionally, the PROMIS Physical Function static SF could be used as a brief assessment of disease severity and global disease impact for longitudinal tracking and comparison of patientreported outcomes between studies of this clinical population.
Evaluation of PROMIS instruments in clinical populations
is an incipient area of patient-centered outcomes research. Recent work has examined the construct validity of PROMIS computer adaptive testing and static SF instruments in adults with chronic musculoskeletal pain conditions. Broderick et al. [24] reported "known group differences" (an assessment of construct validity) in scores from PROMIS computer adaptive testing and static SFs for Pain Intensity, Pain Interference, Fatigue, and Physical Function between participants with and without knee osteoarthritis. Driban and colleagues [9] expanded these findings by demonstrating the PROMIS Pain Interference, Physical Function, Anxiety, and Depression static SFs were highly associated with legacy measures (e.g., WOMAC) of general bodily pain, physical function, and overall mental health in adults with knee osteoarthritis. The current study used principal component analyses and weighted the PROMIS static SF subscales similarly to the FIQR subscales prior to statistical analysis to assess construct (convergent) validity. As the PROMIS 'total' score was highly correlated with the FIQR total score, these findings suggest that many of the PROMIS static SFs used in this study adequately capture disease severity and global disease impact in women with fibromyalgia. However, clinicians and researchers may have more focused questions related to specific aspects of disease severity and global disease impact that would benefit from parsimonious selection of PROMIS static SF instruments.
Physical function is one of the core symptom domains identified by the OMERACT and IMPAACT groups for assessing patient-reported outcomes in individuals with fibromyalgia [16, 17] . Perceived physical function is one of the primary elements of global disease impact and health-related quality of life in adults with fibromyalgia [25] . Also, patients with fibromyalgia report physical function as an important treatment outcome [12, 16, 25, 26] . In the present study, the PROMIS 'physical function' domain was highly correlated with the FIQR 'function' domain, and had the greatest unique contribution to the variance in the FIQR total score. Together these results suggest that the PROMIS Physical Function static SF satisfactorily captures perceived physical function, and that perceived physical function is a key component of disease severity and global disease impact in women with fibromyalgia. However, there was only a moderate correlation between the PROMIS 'physical function' domain and the FIQR total score. This indicates that although the PROMIS Physical Function static SF captures many elements of disease severity and global disease impact as reflected in the PROMIS total score, there are some aspects that remain unexplained.
Construct validity of the PROMIS Physical Function computer adaptive testing and static SF instruments has been evaluated in other chronic musculoskeletal pain populations. For example, the PROMIS Physical Function SF was better correlated with the SF-36 Physical Function subscale, a legacy measure of perceived whole body physical function, than with disease-specific measures of joint function (WOMAC) in participants with knee osteoarthritis [9] . Similarly, the PROMIS Physical Function computer adaptive test was highly correlated with the Modified Health Assessment Questionnaire (MHAQ), a legacy measure of perceived function, in participants with rheumatoid arthritis [27, 28] . The FIQR 'function' domain subscales administered in the current study were developed as a disease-specific measure of perceived physical function in fibromyalgia. Consequently, the FIQR 'function' domain is not widely administered in other rheumatologic populations, which precludes comparison of scores. Therefore, perceived physical function using the PROMIS Physical Function static SF may sufficiently capture perceived physical function in people with fibromyalgia, which could then be compared with scores from other populations of adults with chronic musculoskeletal pain conditions. The PROMIS static SFs included in the 'global' and 'symptom' domains align with many biopsychosocial factors associated with fibromyalgia [4] . Khanna and colleagues [4] assert that global health and fatigue, in addition to physical function, are relevant constructs to measure in rheumatologic patient populations. Results from the current study show that the PROMIS 'global' and 'symptom' domain scores were moderately correlated with the FIQR 'overall impact' and 'symptom' domain scores, respectively. In addition, the PROMIS 'global' and 'symptom' domains accounted for up to 14% of the variance in the FIQR total score when added to the multiple regression model. However, because of the high collinearity of the PROMIS 'symptom' and 'global' domain scores, the unique contribution of either variable to the model was negligible, suggesting that the PROMIS 'global' and 'symptom' domains measure similar constructs in participants with fibromyalgia. Others have reported similar observations in that scores from PROMIS static SFs that query biopsychosocial factors such as pain, depression, and anxiety were highly correlated with each other, and likely measure similar constructs in other musculoskeletal pain conditions [9, 10] . Further, select items on the PROMIS SF v1.0-1.1 Global static SF highly correlate with scores from the Physical Function, Fatigue, Depression, and Pain Impact item banks in a combined sample of adults with and without chronic musculoskeletal pain [7] . Taken together, current and prior studies suggest that the PROMIS static SFs included in the 'global' and 'symptom' domains capture similar constructs. Therefore, any of the static SFs included in the 'global' and 'symptom' domains could be administered collectively or individually for clinical or research questions related to global health.
Diffuse musculoskeletal pain is the most clinically important feature reported by people with fibromyalgia [12, 26] . Interestingly, the current study showed that Pain Behavior and Pain Interference static SF scores had the lowest correlations with the FIQR 'symptom' subscale scores, and did not significantly improve the relationship to the FIQR 'symptom' domain and FIQR total score. Similarly, pain, stiffness, and tenderness items included in the FIQR 'symptom' domain have low to moderate correlations with the eight SF-36 subscale scores [19] . In a similar vein, Kean et al. [29] suggested that the BPI and 3-item pain scale (PEG) demonstrated better responsiveness and were more sensitive to change in self-reported measures of pain in patients with chronic musculoskeletal pain than the PROMIS Pain Interference static SFs. One possible explanation is that pain is but one of multiple symptoms assessed with the FIQR 'symptom' subscale. These subscale questions probe the intensity of multiple symptoms (including pain), not behavioral responses to the symptoms or their level of interference with activities. Alternatively, enrollment in the FAST study required a pain level of 4 or above, which may have reduced the variability of the pain response.
Some limitations exist with the current data set. First, the current investigation featured a cohort of women with fibromyalgia, so any of the conclusions drawn from the results may not be applicable to men with fibromyalgia. However, fibromyalgia disproportionately affects women, and therefore, the results obtained from this study apply to a sizable portion of the patient population. This sample was also primarily Caucasian, limiting generalizability of the results to other racial and ethnic groups. Another limitation of this study is the use of a single legacy measure of disease severity to determine the convergent validity of PROMIS static SFs in adults with fibromyalgia. Future investigations could build on these findings by evaluating the reliability and convergent validity of the PROMIS static SFs with other legacy measures of disease severity, global disease impact, and physical function such as the Fibromyalgia Survey Questionnaire (FSQ), Polysymptomatic Distress Scale (PSD), or the SF-36 subscales. Lastly, as stated above, the entrance criteria to the study was a pain intensity of four or greater, which may limit the variability of the population particularly in those with less severe fibromyalgia.
The multidimensional nature of fibromyalgia necessitates selection of instruments that best encapsulate disease severity across multiple domains. Although the FIQR [4] . Furthermore, PROMIS static SFs are freely accessible, easy to score, and perform similarly to larger item banks used in computer adaptive testing [3, 8] .
Findings from the current study show that many of the PROMIS static SF instruments demonstrate convergent validity with subscale items on the FIQR. These results highlight the potential utility of select PROMIS static SFs for assessment and longitudinal tracking of outcomes in this patient population.
